X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-01 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $24.08 | -500 | 73,409 | -1% | -$12,041 | ||||||
| D | 2025-05-02 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $14.60 | -1,327 | 23,526 | -5% | -$19,374 | |||||
| D | 2025-05-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Officer | S - Sale+OE | $32.03 | -3,333 | 82,139 | -4% | -$106,745 | |||||
| D | 2025-05-02 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $14.60 | -3,498 | 62,773 | -5% | -$51,071 | |||||
| D | 2025-05-01 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Chief Program Officer | S - Sale+OE | $32.40 | -5,875 | 50,554 | -10% | -$190,324 | |||||
2025-05-02 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale | $11.33 | -6,198 | 33,724 | -16% | -$70,243 | ||||||
2025-04-30 | ABT | Abbott Laboratories | Blount Sally E. | Dir | S - Sale | $129.66 | -2,600 | 34,058 | -7% | -$337,116 | ||||||
| D | 2025-05-01 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $72.57 | -6,830 | 618,610 | -1% | -$495,668 | |||||
2025-05-01 | IONS | Ionis Pharmaceuticals Inc | Hayden Michael R | Dir | P - Purchase | $31.86 | +15,000 | 52,219 | +40% | +$477,900 | ||||||
| D | 2025-05-01 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $300.93 | -11,000 | 36,781 | -23% | -$3,310,201 | |||||
| D | 2025-05-01 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $14.00 | -311 | 110,886 | 0% | -$4,354 | |||||
| M | 2024-12-18 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $13.26 | +207,436 | 926,943 | +29% | +$2,749,916 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Fisher Andrew | GC | S - Sale+OE | $8.98 | -26,072 | 359,993 | -7% | -$234,127 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Zaccardelli David | Pres, CEO | S - Sale+OE | $8.98 | -90,360 | 14,377,176 | -1% | -$811,433 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Rickard Kathleen A. | Chief Medical Officer | S - Sale+OE | $8.98 | -34,384 | 2,660,656 | -1% | -$308,768 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Hahn Mark W | CFO | S - Sale+OE | $8.98 | -90,360 | 13,466,000 | -1% | -$811,433 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Sinha Vikas | Dir | S - Sale+OE | $8.92 | -20,000 | 74,440 | -21% | -$178,416 | |||||
| M | 2025-04-30 | ACRV | Acrivon Therapeutics, Inc. | Perceptive Advisors LLC | 10% | S - Sale | $1.38 | -736,767 | 3,104,139 | -19% | -$1,017,919 | |||||
| DM | 2025-04-29 | KNSA | Kiniksa Pharmaceuticals International, Plc | Moat Ross | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $25.96 | -87,269 | 9,415 | -90% | -$2,265,339 | |||||
| DM | 2025-04-29 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $26.56 | -88,395 | 27,009 | -77% | -$2,347,335 | |||||
| D | 2025-04-29 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $65.09 | -7,031 | 19,209 | -27% | -$457,663 | |||||
2025-04-29 | RYTM | Rhythm Pharmaceuticals, Inc. | Mazabraud Yann | EVP, Head of International | S - Sale | $65.08 | -6,745 | 37,655 | -15% | -$438,946 | ||||||
| D | 2025-04-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $74.56 | -4,000 | 48,034 | -8% | -$298,240 | |||||
| D | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $11.50 | -3,377 | 61,516 | -5% | -$38,841 | |||||
| D | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $11.50 | -2,894 | 37,318 | -7% | -$33,286 | |||||
| D | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $11.50 | -2,438 | 39,922 | -6% | -$28,041 | |||||
| D | 2025-04-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $18.69 | -3,250 | 23,000 | -12% | -$60,738 | |||||
2025-04-30 | ZNTL | Zentalis Pharmaceuticals, Inc. | Myers Scott Dunseth | Dir | P - Purchase | $1.40 | +21,000 | 281,192 | +8% | +$29,373 | ||||||
| D | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale+OE | $1.05 | -1,963 | 3,208,793 | 0% | -$2,061 | |||||
2025-04-28 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale | $14.24 | -455 | 183,849 | 0% | -$6,479 | ||||||
| D | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir, 10% | S - Sale+OE | $1.05 | -2,425 | 4,309,860 | 0% | -$2,546 | |||||
| D | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale+OE | $1.05 | -4,386 | 6,718,670 | 0% | -$4,605 | |||||
| M | 2025-04-25 | ACRV | Acrivon Therapeutics, Inc. | Perceptive Advisors LLC | 10% | S - Sale | $1.81 | -1,519,952 | 3,840,906 | -28% | -$2,744,946 | |||||
2025-04-25 | BMY | Bristol Myers Squibb Co | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | P - Purchase | $47.58 | +4,250 | 83,513 | +5% | +$202,215 | ||||||
| DM | 2025-04-25 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $14.00 | -5,689 | 110,886 | -5% | -$79,658 | |||||
2025-04-29 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $40.96 | -5,000 | 421,795 | -1% | -$204,800 | ||||||
| D | 2025-04-25 | MRK | Merck & Co., Inc. | Smart Dalton E. III | SVP Fin. - Global Controller | S - Sale+OE | $82.76 | -4,262 | 7,778 | -35% | -$352,723 | |||||
2025-04-25 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $9.88 | +3,600 | 5,570,602 | 0% | +$35,568 | ||||||
| D | 2025-04-24 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $41.03 | -6,250 | 169,721 | -4% | -$256,438 | |||||
| A | 2025-02-07 | ZBIO | Zenas Biopharma, Inc. | Xiao Ting | Dir | P - Purchase | $7.76 | +10,000 | 10,000 | New | +$77,600 | |||||
2025-04-25 | CNTA | Centessa Pharmaceuticals Plc | Weinhoff Gregory M | Chief Business Officer | S - Sale | $13.61 | -11,742 | 122,279 | -9% | -$159,857 | ||||||
2025-03-13 | MLYS | Mineralys Therapeutics, Inc. | Slingsby Brian Taylor | Dir, 10% | P - Purchase | $13.50 | +259,259 | 8,903,838 | +3% | +$3,499,997 | ||||||
2025-04-22 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $48.74 | -2,804 | 273,234 | -1% | -$136,656 | ||||||
2025-04-23 | KPTI | Karyopharm Therapeutics Inc. | Rangwala Reshma | EVP, Chief Medical Officer | S - Sale | $6.17 | -419 | 28,853 | -1% | -$2,585 | ||||||
2025-04-22 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $34.11 | -75,000 | 6,080,851 | -1% | -$2,558,025 | ||||||
2025-04-22 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $7.16 | -718 | 65,039 | -1% | -$5,139 | ||||||
| D | 2025-04-21 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Officer | S - Sale+OE | $30.00 | -3,334 | 82,139 | -4% | -$100,020 | |||||
2025-04-21 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | SVP, COMM, MEDICAL AFFAIRS | S - Sale | $9.00 | -4,000 | 370,038 | -1% | -$36,000 | ||||||
2025-04-21 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $16.07 | -5,000 | 997,688 | 0% | -$80,366 | ||||||
2025-04-21 | KNSA | Kiniksa Pharmaceuticals International, Plc | Moat Ross | CHIEF COMMERCIAL OFFICER | S - Sale | $20.29 | -18,259 | 9,415 | -66% | -$370,475 | ||||||
2025-04-22 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale | $46.00 | -1,756 | 61,065 | -3% | -$80,776 | ||||||
2025-04-21 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $13.67 | -2,450 | 263,152 | -1% | -$33,492 | ||||||
| D | 2025-04-21 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $10.22 | -100,000 | 1,116,345 | -8% | -$1,022,000 | |||||
| M | 2025-04-21 | CNTA | Centessa Pharmaceuticals Plc | Saha Saurabh | CEO | S - Sale | $12.39 | -55,000 | 259,017 | -18% | -$681,576 | |||||
| DM | 2024-04-30 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% | P - Purchase | $0.16 | +197,408 | 110,909,455 | 0% | +$31,585 | |||||
| D | 2025-04-22 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $38.11 | -2,000 | 140,255 | -1% | -$76,220 | |||||
| D | 2025-04-21 | UTHR | United Therapeutics Corp | Dwek Raymond | Dir | S - Sale+OE | $285.57 | -3,000 | 1,750 | -63% | -$856,710 | |||||
2025-04-17 | PEPG | Pepgen Inc. | McArthur James G | Pres, CEO | P - Purchase | $1.36 | +10,000 | 113,913 | +10% | +$13,550 | ||||||
2025-04-17 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $8.98 | +5,400 | 5,567,002 | 0% | +$48,492 | ||||||
2025-04-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $16.42 | -5,000 | 985,392 | -1% | -$82,096 | ||||||
| D | 2025-04-21 | CYTK | Cytokinetics Inc | Wierenga Wendall | Dir | S - Sale+OE | $38.46 | -20,000 | 24,848 | -45% | -$769,200 | |||||
2025-04-17 | ESPR | Esperion Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale | $0.98 | -108 | 370,218 | 0% | -$106 | ||||||
2025-04-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | CFO | S - Sale | $0.96 | -8 | 481,702 | 0% | -$8 | ||||||
| D | 2025-04-17 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $283.78 | -11,000 | 36,781 | -23% | -$3,121,543 | |||||
| M | 2025-04-16 | ZYME | Zymeworks Inc. | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $11.32 | +128,713 | 17,828,487 | +1% | +$1,456,408 | |||||
| D | 2025-04-15 | NAMS | Newamsterdam Pharma Co N.V. | Kling Douglas F | COO | S - Sale+OE | $0.00 | -100,000 | 44,000 | -69% | -$0 | |||||
| D | 2025-04-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $68.94 | -27,000 | 249,062 | -10% | -$1,861,504 | |||||
| D | 2025-04-16 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $28.37 | -680 | 56,660 | -1% | -$19,292 | |||||
| D | 2025-04-16 | IONS | Ionis Pharmaceuticals Inc | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | S - Sale+OE | $28.36 | -3,016 | 11,199 | -21% | -$85,534 | |||||
| D | 2025-04-16 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $28.40 | -3,928 | 34,997 | -10% | -$111,555 | |||||
2025-04-15 | ETNB | 89Bio, Inc. | Le-Nguyen Quoc | See Remarks | S - Sale | $5.95 | -15,329 | 343,073 | -4% | -$91,208 | ||||||
2025-04-15 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.90 | +15,000 | 1,113,460 | +1% | +$13,500 | ||||||
| D | 2025-04-15 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale+OE | $37.91 | -9,073 | 95,034 | -9% | -$343,962 | |||||
| D | 2025-04-14 | BBIO | Bridgebio Pharma, Inc. | Ellis Andrea | Dir | S - Sale+OE | $35.00 | -10,000 | 12,000 | -45% | -$350,000 | |||||
| D | 2025-04-14 | BGNE | Beigene, Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $242.66 | -41,760 | 10,060,378 | 0% | -$10,133,595 | |||||
2025-04-14 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale | $13.57 | -5,964 | 584,801 | -1% | -$80,931 | ||||||
2025-04-14 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $13.57 | -14,130 | 2,594,682 | -1% | -$191,744 | ||||||
2025-04-15 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale | $13.57 | -3,406 | 214,744 | -2% | -$46,219 | ||||||
2025-04-14 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale | $13.57 | -8,283 | 396,315 | -2% | -$112,400 | ||||||
2025-04-14 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $13.57 | -3,714 | 265,602 | -1% | -$50,399 | ||||||
2025-04-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $9.57 | -8,500 | 460,642 | -2% | -$81,310 | ||||||
| D | 2025-04-14 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $20.48 | -12,000 | 77,363 | -13% | -$245,812 | |||||
| D | 2025-04-15 | CYTK | Cytokinetics Inc | Henderson John T | Dir | S - Sale+OE | $38.66 | -3,190 | 66,431 | -5% | -$123,325 | |||||
| D | 2025-04-15 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $70.16 | -6,830 | 618,610 | -1% | -$479,177 | |||||
2025-04-15 | RNXT | Renovorx, Inc. | Bagai Shaun | CEO | P - Purchase | $0.91 | +7,500 | 320,040 | +2% | +$6,821 | ||||||
| D | 2025-04-14 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $13.57 | -1,856 | 184,304 | -1% | -$25,186 | |||||
| D | 2025-04-14 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $14.53 | -11,366 | 111,686 | -9% | -$165,185 | |||||
2025-04-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $12.06 | -10,757 | 215,340 | -5% | -$129,684 | ||||||
2025-04-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $12.19 | -15,319 | 862,289 | -2% | -$186,803 | ||||||
2025-03-31 | ASMB | Assembly Biosciences, Inc. | McHutchison John G | Dir | S - Sale | $9.85 | -757 | 18,347 | -4% | -$7,455 | ||||||
| D | 2025-04-14 | SDGR | Schrodinger, Inc. | Akinsanya Karen | Pres of R, D, Therapeutics | S - Sale+OE | $25.09 | -16,723 | 15,625 | -52% | -$419,570 | |||||
| D | 2025-04-14 | UTHR | United Therapeutics Corp | Dwek Raymond | Dir | S - Sale+OE | $285.16 | -3,000 | 1,750 | -63% | -$855,480 | |||||
| M | 2025-04-10 | RMTI | Rockwell Medical, Inc. | Irrevocable Larson Family Investment Trust | 10% | P - Purchase | $1.07 | +87,500 | 3,557,500 | +3% | +$94,018 | |||||
| M | 2025-04-02 | NBY | Novabay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP | 10% | P - Purchase | $0.56 | +28,731 | 1,020,300 | +3% | +$15,967 | |||||
| M | 2025-03-26 | NBY | Novabay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP | 10% | P - Purchase | $0.60 | +123,365 | 991,569 | +14% | +$74,519 | |||||
| M | 2025-03-18 | NBY | Novabay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP | 10% | P - Purchase | $0.62 | +49,927 | 868,204 | +6% | +$30,718 | |||||
| M | 2025-03-10 | NBY | Novabay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP | 10% | P - Purchase | $0.62 | +64,175 | 818,277 | +9% | +$39,503 | |||||
| M | 2025-02-25 | NBY | Novabay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP | 10% | P - Purchase | $0.61 | +48,930 | 754,102 | +7% | +$29,858 | |||||
| M | 2025-02-03 | NBY | Novabay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP | 10% | P - Purchase | $0.66 | +84,487 | 705,172 | +14% | +$55,527 | |||||
| M | 2025-01-27 | NBY | Novabay Pharmaceuticals, Inc. | Poplar Point Capital Partners LP | 10% | P - Purchase | $0.66 | +102,388 | 620,685 | +20% | +$67,700 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |